Page 8 - Topline News Today

Reported positive topline data from the completed Part A safety lead-in of the THIO-101 Phase 2 go-to-market trial in advanced Non-Small Cell Lung Cancer and commenced recruitment in Part B... | May 8, 2023

Announced positive topline data from the Phase 3 EMERGENT-3 trial of KarXT in schizophrenia in the first quarter of 2023 On track to submit New Drug Application for KarXT in schizophrenia with the... | May 4, 2023

Completed enrollment for Phase 2 SEQUEL trial in mild-to-moderate Alzheimer’s disease ; topline results expected 2Q 2023 SHINE trial currently enrolling patients with first patient in Spain... | May 4, 2023

Sustained Topline Growth, Expanding Margins TORONTO, May 04, 2023 -- Altus Group Limited , a leading provider of asset and fund intelligence for commercial real estate , announced today its... | May 4, 2023

EQS-Ad-hoc: Majorel Group Luxembourg S.A. / Key word(s): Quarter Results/Quarter Results Majorel Group Luxembourg S.A.: Majorel reports strong topline growth of +11% for Q1 2023 03-May-2023 / 08:00

EQS-Ad-hoc: Majorel Group Luxembourg S.A. / Key word: Quarter Results/Quarter Results Majorel Group Luxembourg S.A. : Majorel reports strong topline growth of +11% for Q1 2023 03-May-2023 /... | May 3, 2023

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with... | May 1, 2023

Topline Data from the Two-Year Endpoints in the Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis May 1, 2023 ... | May 1, 2023

EARNINGS/SALES RELEASESIn the Q1-2023, Ebro Foods once again demonstrated its resilience in the face of the current macroeconomic environment. The company’s topline was largely bolstered by its... | April 28, 2023